| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
ImageneBio, Inc.$6
+0.17 (+2.92%)
D 39Pipeline Score Undervalued Biotech · Commercial
Market Cap
65.66 M
EPS
-5.26
P/E Ratio
-
Value Trade
35.19 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.96 M
Operating CF
-14.80 M
Total Assets
136.68 M
Total Liabilities
13.36 M
Equity
123.33 M
D/E Ratio
12,345
-5.12 %
Week
-5.28 %
1 Month
-17.99 %
3 Month
-22.45 %
6 Month
-99.8 %
5 Year
-99.83 %
All Time
Cash Data
Cash Position
117.21 M
Monthly Burn
4.93 M
Runway
21.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
4.87 K
52 Week Range
3.94 - 216
% held by Insiders
36.61 %
% held by Institutions
29.93 %
Enterprise Value
-43.40 M
Total Shares
11.27 M
Short %
5.29 %
Float Shares
8.99 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ImageneBio, Inc.
90Total events
3Upcoming
16Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 87
Jun 4, 2026
May 15, 2026
◆Oral PresentationIMG-007Presentation
Oral presentation of preclinical data at SID Meeting
inflammatory and autoimmune diseasesource ↗
May 2026
Apr 13, 2026
▼Equity OfferingCorporate
ImageneBio announces $30 million private placement led by Coastlands Capital
Apr 2026
▼Equity OfferingCorporate
Completed private placement for gross proceeds of approximately $30 million
Mar 10, 2026
◆Oral PresentationPresentation
Management to participate in fireside chat at Leerink Global Healthcare Conference
Feb 16, 2026
Drug Pipeline Intelligence
D39
Pipeline Score $90M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored4.6x
rNPV / MCap Top 54%
Micro Cap (rank 418 of 906)
Percentile RankImageneBio, Inc. faces pipeline headwinds (39/100), with $1.6B risk-adjusted pipeline value, led by IMG-007 in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMG-007 Small molecule | Atopic Dermatitis | Phase 2 | NCT07037901 | 33% | $1.4B | RECRUITING | 220 | STALLED | B (78) | Oct 1, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IK-930 | epithelioid hemangioendothelioma | Phase 1 | 2023-11-09 | patients treated: 26; tumor shrinkage: encouraging signs; treatment related proteinuria: 3 out of 26 patients; proteinuria grade: grade 1-2 Read More | Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selecti Read More | |
IK-930 | epithelioid hemangioendothelioma | Phase 1 | 2023-11-09 | patients treated: 26; tumor shrinkage: encouraging signs; treatment related proteinuria: 3 out of 26 patients; proteinuria grade: grade 1-2 Read More | Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selecti Read More | |
IK-930 | epithelioid hemangioendothelioma | Phase 1 | 2023-11-09 | patients treated: 26; tumor shrinkage: encouraging signs; treatment related proteinuria: 3 out of 26 patients; proteinuria grade: grade 1-2 Read More | Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selecti Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMAImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
ImageneBio, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Kristin Yarema will present at the event, which will also include one-on-one meetings with management. The company is focused on developing therapies for immunological and autoimmune diseases, with ongoing clinical trials for its product IMG-007.
Read more →IMAImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio reported its Q1 2026 financial results and provided updates on its lead program, IMG-007, which is advancing into a Phase 2 clinical trial for alopecia areata. The company secured $30 million in financing, extending its cash runway into early 2028. IMG-007 is notable for its non-T cell-depleting mechanism and is currently being evaluated in a Phase 2b trial for atopic dermatitis with topline data expected in late 2027.
Read more →IMAImageneBio Announces $30 Million Private Placement
ImageneBio has announced a $30 million private placement with institutional investors to fund the development of its drug IMG-007 for alopecia areata and atopic dermatitis. The company is optimistic about the progress of its Phase 2b ADAPTIVE trial and the potential of IMG-007 as a disease-modifying treatment. The placement involves pre-funded warrants and is led by Coastlands Capital.
Read more →IMAImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio, Inc. announced the granting of equity awards to two new employees as part of their employment inducement under Nasdaq Listing Rule 5635(c)(4). The awards include 38,442 restricted stock units and 43,000 non-qualified stock options, with a vesting schedule over four years. This move reflects the company's commitment to attracting talent while adhering to regulatory requirements.
Read more →IMAImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the promising clinical progress of its lead candidate, IMG-007, an OX40 antagonist. The company has observed no significant tolerability issues, differentiating it from its competitors. With a robust financial position, bolstered by recent funding and a merger, it plans to advance its Phase 2b ADAPTIVE trial in atopic dermatitis, while remaining aware of competition and potential safety concerns in the field. An upcoming presentation at the SID Meeting will showcase additional preclinical data on IMG-007's innovative profile.
Read more →IMAImageneBio to Participate in Leerink Global Healthcare Conference
ImageneBio, Inc. will participate in the 2026 Leerink Global Healthcare Conference from March 8-11 in Miami, Florida. The company will engage in a fireside chat and hold one-on-one meetings to discuss its clinical-stage programs, particularly IMG-007, which is in Phase 2b trials for atopic dermatitis. This involvement highlights the company's commitment to advancing its therapeutic developments.
Read more →IMAImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio has appointed Dr. Ben Porter-Brown as Chief Medical Officer to lead its clinical organization and oversee the Phase 2b ADAPTIVE trial for atopic dermatitis. With over 20 years of experience in autoimmune and inflammatory diseases, Dr. Porter-Brown aims to enhance the company's clinical capabilities and expand its trial sites internationally. His expertise in OX40 signaling inhibitors is expected to significantly benefit the development of Imagene's drug IMG-007.
Read more →IMAImageneBio Corporate Overview Fourth Quarter 2025 Disclaimer and forward-looking statements This investor presentation and any accompanying oral commentary have been prepared by ImageneBio, Inc. (the Company) for informa
ImageneBio, Inc. presented an overview of its corporate status and future prospects, highlighting its immunology innovations, particularly IMG-007, aimed at treating atopic dermatitis. The presentation emphasized the current unmet needs in the atopic dermatitis market, where existing treatments fall short for a significant portion of patients. ImageneBio has a well-established funding runway anticipated to extend until the end of 2027, supporting their ongoing Phase 2b clinical studies. However, risks surrounding the clinical development process and dependency on external partners were also noted.
Read more →IMAImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team $142.6 million cash and cash equ
ImageneBio reported its third quarter 2025 financial results, revealing a cash balance of $142.6 million following a reverse merger and concurrent financing. The company provided an update on the ongoing Phase 2b ADAPTIVE study of its anti-OX40 monoclonal antibody, IMG-007, focusing on atopic dermatitis, highlighting strong patient enrollment and planned protocol amendments to optimize the trial. Leadership changes and upcoming data presentations at a key summit further indicate an active progression in their clinical programs. However, the firm also noted a substantial net loss and ongoing risks linked to clinical and regulatory developments.
Read more →IMAI MAGENE B IO , I NC . 2025 E QUITY I NDUCEMENT P LAN A DOPTED BY THE B OARD OF D IRECTORS : J ULY 28, 2025 1. G ENERAL . (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of El
I Magene Bio, Inc. has announced the adoption of a 2025 equity inducement plan by its Board of Directors. The plan is designed to attract and retain eligible employees by providing them with incentives linked to the company's stock performance. The Board can grant nonstatutory stock options and restricted stock units under specific guidelines dictated by Nasdaq rules. The plan includes provisions on share reserves and eligibility, aiming to promote employee engagement and commitment to the company's success.
Read more →IMACorporate Overview July 2025 Disclaimer This presentation contains "forward-looking statements" under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.'
ImageneBio, Inc. has outlined its forward-looking statements regarding the development of its lead program, IMG-007, aimed at treating atopic dermatitis (AD) and alopecia areata (AA). The company has reported promising initial results from clinical trials, showing rapid and sustained improvements in patient scores for AD. However, the presentation highlights significant risks, including the uncertainties involved in clinical trials and the overall financial health of the company. The completion of a merger in July 2025 is expected to enhance Imagene's strategic position in the biopharmaceutical industry.
Read more →IMAInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million The combined company will operate under the name ImageneBio, Inc. and will begin trading on N
Inmagene Biopharmaceuticals has completed its merger with Ikena Oncology, forming a new entity named ImageneBio, Inc., which will begin trading on Nasdaq under the ticker symbol IMA on July 28, 2025. The merger is accompanied by a $75 million private placement aimed at advancing the clinical development of IMG-007, a monoclonal antibody targeting OX40 for treating immunological diseases. ImageneBio is set to continue its Phase 2b trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline results expected in late 2026.
Read more →IMAIkena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals Combined Company to Trade on Nasdaq Under Ticker IMA Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON, MA
Ikena Oncology has announced that stockholders have approved the merger with Inmagene Biopharmaceuticals, enabling the combined company to list on Nasdaq under the ticker IMA. Additionally, a reverse stock split of 1-for-12 has been confirmed, reducing the total number of shares. The merger's completion and the new trading arrangements are expected to initiate around the end of July. Ikena is known for its development of therapies targeting cancer, while Inmagene has focused on therapeutics for immunological and inflammatory diseases.
Read more →IMAIkena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote FOR Proposed Merger with Inmagene Biopharmaceuticals BOSTON
Ikena Oncology has announced that Institutional Shareholder Services and Glass Lewis have recommended stockholders approve the proposed merger with Inmagene Biopharmaceuticals. This recommendation is crucial as Ikena's Annual Meeting is set for July 15, 2025, where stockholders will vote on this and other proposals. The merger aims to leverage Inmagene's lead candidate, IMG-007, which has shown promise in treating atopic dermatitis. The merger's approval could significantly impact Ikena's market position and growth potential in immunological and inflammatory diseases.
Read more →IMAInmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis The ADAPTIVE Phase 2b trial evaluates
Inmagene Biopharmaceuticals has announced the successful dosing of the first patient in its global Phase 2b trial (ADAPTIVE) for IMG-007, aimed at treating moderate-to-severe atopic dermatitis (AD). This trial will explore various dosing regimens with about 220 participants enrolled. The primary endpoint is the percentage change in the Eczema Area and Severity Index (EASI) score at Week 20. The anticipated topline results are expected in Q4 2026, which will inform future Phase 3 studies.
Read more →IMAAdditional Information and Where to Find It Investors and security holders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Ikena with the SEC through the website maint
Inmagene Biopharmaceuticals has entered into a merger agreement with Ikena Oncology, forming a new entity named ImageneBio, which will focus on developing IMG-007, a monoclonal antibody for atopic dermatitis. The merger is anticipated to generate approximately $175 million, including $75 million from a private placement, to support the drug's further development. The newly formed company is expected to list on NASDAQ under the ticker IMA. The transaction is slated to close in mid-2025, pending customary approvals.
Read more →IMAIkena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $1
Ikena Oncology has announced the discontinuation of the IK-930 clinical program, a decision attributed to their focus on maximizing shareholder value and exploring strategic options. Concurrently, the company is progressing with the clinical development of IK-595, which targets RAS and RAF mutant cancers and has shown promising pharmacokinetics and pharmacodynamics. The firm ended the first quarter with $157.3 million, fortifying its cash position to explore potential partnerships and development paths.
Read more →IMAIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise D
Ikena Oncology has appointed Dr. Caroline Germa, an experienced oncologist with over 25 years in pharmaceutical development, as its new Chief Medical Officer. This leadership change comes following the resignation of Dr. Sergio Santillana. Dr. Germa is expected to steer the company's clinical development strategy, especially regarding its oncology programs IK-930 and IK-595, and aims to expand access for patients with unmet needs. The company highlighted Dr. Germa's previous roles in major pharmaceutical firms, indicating her capability to enhance their innovative clinical offerings.
Read more →IMAIkena Oncology Outlines Key Priorities and Provides Corporate Updates IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared saf
Ikena Oncology provided a corporate update outlining its strategic focus on advancing clinical programs IK-930 and IK-595. The company announced that the optimized formulation of IK-930 is now in clinical development, with additional data expected in the second half of 2024. Furthermore, IK-595 has cleared the safety evaluation for its first treatment cohort. Ikena maintains a strong financial position, with cash reserves projected to last into the second half of 2026, as they streamline resources to concentrate on core oncology programs.
Read more →IMAIkena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selecti
Ikena Oncology reported positive initial dose escalation data for its IK-930 Phase I trial, demonstrating a favorable safety profile and clinical activity in patients with difficult-to-treat epithelioid hemangioendothelioma. Out of 26 patients treated, encouraging signs of tumor shrinkage were noted, particularly for EHE, as well as symptomatic improvements reported by patients. The company has reported adequate funding through 2026 to support its clinical efforts and is planning further updates on the drug's progress in the second half of 2024.
Read more →IMAIkena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena s targeted on
Ikena Oncology has successfully acquired Pionyr Immunotherapeutics in an all-stock transaction, wherein Ikena received approximately $43 million in net cash at closing. This acquisition aims to strengthen Ikena's targeted oncology pipeline, particularly enhancing the development of programs like IK-930 and IK-595. Leaders from both companies have expressed enthusiasm about the merger, highlighting the strategic fit and potential for growth. Despite the positive outlook, there are inherent risks associated with the forward-looking statements made regarding the future of their oncology programs.
Read more →IMAIkena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalat
Ikena Oncology announced its first quarter 2023 financial results, highlighting advancements in their targeted oncology pipeline. The lead program, IK-930, continues through dose escalation without dose-limiting toxicities observed. Financial performance showed increased collaboration revenue, primarily due to operational shifts, and the company completed a $40 million underwritten offering to extend its runway. The novel profile of IK-595, a MEK-RAF complex inhibitor, was also discussed during the updates.
Read more →IMAIkena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting IK-930 is a potent
Ikena Oncology presented the differentiation profile of their novel Hippo-pathway inhibitor, IK-930, at the AACR 2023 Annual Meeting. IK-930 selectively binds TEAD1, demonstrating a favorable therapeutic index with minimal renal toxicity, unlike panTEAD inhibitors. Non-human primate studies showed no signs of renal toxicity, and there is potential for IK-930 to delay or reverse resistance to other therapies. The ongoing Phase 1 program in Hippo mutated cancers aims to establish IK-930 as a novel treatment option.
Read more →IMAIkena Oncology Appoints Owen Hughes as Board Chair Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management r
Ikena Oncology Appoints Owen Hughes as Board Chair Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role BOSTON, Dec. 19, 2022 Ikena Oncology, Inc. (Nasdaq: I
Read more →IMAIkena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinica
Read more →IMAIkena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carc
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed part
Read more →IMAIkena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & dev
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & BOSTON, April 13, 2022 Ikena Oncology, Inc. (Nasdaq: IKNA, Ik
Read more →IMAIkena Appoints Richard Wooster, Ph.D., to its Board of Directors BOSTON
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors BOSTON, Jan. 26, 2022 Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena ), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.
Read more →IMANovember 2021 Disclaimer This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our
This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects
Read more →IMAIkena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEA
Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930 Progressing IK-175 clinical trial m
Read more →IMAIkena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Closed IPO and Raised $144 Million in Gross Proceeds to Fund Targeted Oncology Therapies IND Submissions for Lead
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Closed IPO and Raised $144 Million in Gross Proceeds to Fund Targeted Oncology Therapies IND Submissions for Lead Targeted Oncology Program, IK-930, and BMS-partnered pr
Read more →IMAIkena Oncology Appoints Dr. Maria Koehler to its Board of Directors Boston, MA
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors Boston, MA April 15, 2021 Ikena Oncology, Inc. (Nasdaq: IKNA) ( Ikena ), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread o
Read more →Competitive Position
How IMA ranks across every disease it competes inCompetitive Position is a premium feature
See how IMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial